Merck's Q2 earnings call highlighted strong performance, driven by KEYTRUDA, GARDASIL, and LAGEVRIO.  Management expressed confidence in the company's strategic direction and pipeline, with significant advancements in pneumococcal vaccines and oncology programs.  Guidance was upgraded, reflecting continued momentum and resilience, potentially leading to positive short-term stock price action.
[1]
